Mesenchymal stromal cells targeting kidney disease

Benefits of a combined therapeutic approach

Brooke M. Huuskes, Sharon D. Ricardo

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

Mesenchymal stromal cells (MSCs) show great promise in ameliorating kidney disease. These multipotent fibroblast‐like stromal cells can migrate to damaged kidneys, where they selectively home to inflammatory cues and alter the course of injury. MSCs can elicit endogenous repair through paracrine and/or endocrine mechanisms that modulate the immune response, ultimately allowing for cellular replacement. This chapter reviews new approaches using MSCs as delivery vehicles for secreted proteins and methods for improving efficacy. Despite uncertainty over mechanisms mediating protection, MSCs are currently in clinical trials for a range of acute and chronic diseases, including kidney disorders. The chapter discusses the challenges in applying MSCs in a setting of chronic kidney disease (CKD). It highlights the potential of a combined therapeutic approach using MSCs and an anti‐fibrotic, relaxin, to aid in MSC viability and the promotion of endogenous repair, cellular replacement, and attenuation of fibrosis.
Original languageEnglish
Title of host publicationThe Biology and Therapeutic Application of Mesenchymal Cells
Place of PublicationHoboken, New Jersey
PublisherJohn Wiley & Sons
Chapter51
Pages754-769
Number of pages16
ISBN (Electronic)9781118907375, 9781118907290
ISBN (Print)9781118907511
Publication statusPublished - 2017

Cite this

Huuskes, B. M., & Ricardo, S. D. (2017). Mesenchymal stromal cells targeting kidney disease: Benefits of a combined therapeutic approach. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 754-769). Hoboken, New Jersey: John Wiley & Sons.
Huuskes, Brooke M. ; Ricardo, Sharon D. / Mesenchymal stromal cells targeting kidney disease : Benefits of a combined therapeutic approach. The Biology and Therapeutic Application of Mesenchymal Cells. Hoboken, New Jersey : John Wiley & Sons, 2017. pp. 754-769
@inbook{bb65dc2393a84712be520a3c158eb10a,
title = "Mesenchymal stromal cells targeting kidney disease: Benefits of a combined therapeutic approach",
abstract = "Mesenchymal stromal cells (MSCs) show great promise in ameliorating kidney disease. These multipotent fibroblast‐like stromal cells can migrate to damaged kidneys, where they selectively home to inflammatory cues and alter the course of injury. MSCs can elicit endogenous repair through paracrine and/or endocrine mechanisms that modulate the immune response, ultimately allowing for cellular replacement. This chapter reviews new approaches using MSCs as delivery vehicles for secreted proteins and methods for improving efficacy. Despite uncertainty over mechanisms mediating protection, MSCs are currently in clinical trials for a range of acute and chronic diseases, including kidney disorders. The chapter discusses the challenges in applying MSCs in a setting of chronic kidney disease (CKD). It highlights the potential of a combined therapeutic approach using MSCs and an anti‐fibrotic, relaxin, to aid in MSC viability and the promotion of endogenous repair, cellular replacement, and attenuation of fibrosis.",
author = "Huuskes, {Brooke M.} and Ricardo, {Sharon D.}",
year = "2017",
language = "English",
isbn = "9781118907511",
pages = "754--769",
booktitle = "The Biology and Therapeutic Application of Mesenchymal Cells",
publisher = "John Wiley & Sons",
address = "United States of America",

}

Huuskes, BM & Ricardo, SD 2017, Mesenchymal stromal cells targeting kidney disease: Benefits of a combined therapeutic approach. in The Biology and Therapeutic Application of Mesenchymal Cells. John Wiley & Sons, Hoboken, New Jersey, pp. 754-769.

Mesenchymal stromal cells targeting kidney disease : Benefits of a combined therapeutic approach. / Huuskes, Brooke M.; Ricardo, Sharon D.

The Biology and Therapeutic Application of Mesenchymal Cells. Hoboken, New Jersey : John Wiley & Sons, 2017. p. 754-769.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

TY - CHAP

T1 - Mesenchymal stromal cells targeting kidney disease

T2 - Benefits of a combined therapeutic approach

AU - Huuskes, Brooke M.

AU - Ricardo, Sharon D.

PY - 2017

Y1 - 2017

N2 - Mesenchymal stromal cells (MSCs) show great promise in ameliorating kidney disease. These multipotent fibroblast‐like stromal cells can migrate to damaged kidneys, where they selectively home to inflammatory cues and alter the course of injury. MSCs can elicit endogenous repair through paracrine and/or endocrine mechanisms that modulate the immune response, ultimately allowing for cellular replacement. This chapter reviews new approaches using MSCs as delivery vehicles for secreted proteins and methods for improving efficacy. Despite uncertainty over mechanisms mediating protection, MSCs are currently in clinical trials for a range of acute and chronic diseases, including kidney disorders. The chapter discusses the challenges in applying MSCs in a setting of chronic kidney disease (CKD). It highlights the potential of a combined therapeutic approach using MSCs and an anti‐fibrotic, relaxin, to aid in MSC viability and the promotion of endogenous repair, cellular replacement, and attenuation of fibrosis.

AB - Mesenchymal stromal cells (MSCs) show great promise in ameliorating kidney disease. These multipotent fibroblast‐like stromal cells can migrate to damaged kidneys, where they selectively home to inflammatory cues and alter the course of injury. MSCs can elicit endogenous repair through paracrine and/or endocrine mechanisms that modulate the immune response, ultimately allowing for cellular replacement. This chapter reviews new approaches using MSCs as delivery vehicles for secreted proteins and methods for improving efficacy. Despite uncertainty over mechanisms mediating protection, MSCs are currently in clinical trials for a range of acute and chronic diseases, including kidney disorders. The chapter discusses the challenges in applying MSCs in a setting of chronic kidney disease (CKD). It highlights the potential of a combined therapeutic approach using MSCs and an anti‐fibrotic, relaxin, to aid in MSC viability and the promotion of endogenous repair, cellular replacement, and attenuation of fibrosis.

UR - https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118907474.ch51

M3 - Chapter (Book)

SN - 9781118907511

SP - 754

EP - 769

BT - The Biology and Therapeutic Application of Mesenchymal Cells

PB - John Wiley & Sons

CY - Hoboken, New Jersey

ER -

Huuskes BM, Ricardo SD. Mesenchymal stromal cells targeting kidney disease: Benefits of a combined therapeutic approach. In The Biology and Therapeutic Application of Mesenchymal Cells. Hoboken, New Jersey: John Wiley & Sons. 2017. p. 754-769